(Q37393345)

20 August 2017

1 reference

title

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus (English)

1 reference

20 August 2017

0 references

1 reference

Gerhild Becker

1

0 references

author name string

Hubert E Blum

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

13 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

373

1 reference

20 August 2017

issue

9670

1 reference

20 August 2017

page(s)

1198-1206

1 reference

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Incidence, prevalence, and management of opioid bowel dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The relationship between opioid use and laxative use in terminally ill cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

A long-term survey of morphine in cancer pain patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioid-induced bowel dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Management of postoperative ileus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Review of postoperative ileus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan: a peripherally acting mu-opioid receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Emerging pharmacologic options for treating postoperative ileus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Mechanisms of postoperative ileus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan, a selective peripherally acting mu-opioid antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Increased tumor necrosis factor-alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the delta-opioid agonist SNC 80.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Augmenting effect of opioids on nitrite production by stimulated murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Immunomodulation by opioid peptidomimetic compound.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Postoperative ileus: etiologies and interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

New motilin agonists: a long and winding road

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Lubiprostone for constipation and irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

New therapies in the treatment of postoperative ileus after gastrointestinal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioid antagonists in the treatment of opioid-induced constipation and pruritus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Treatment of opioid-induced gut dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The opioid system in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioids and the gut: pharmacology and current clinical experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The use of quaternary narcotic antagonists in opiate research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Opioid-induced delay in gastric emptying: a peripheral mechanism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Oral methylnaltrexone for opioid-induced constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Methylnaltrexone for opioid-induced constipation in advanced illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Mu-opioid antagonists for opioid-induced bowel dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan∗∗Alvimopan is the official USAN name adopted as of press time. (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Mu opioid receptor antagonists: recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

1 reference

7 January 2021

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Selective postoperative inhibition of gastrointestinal opioid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960139-2

7 January 2021

10.1016/S0140-6736(09)60139-2

Identifiers

DOI

1 reference

20 August 2017

1 reference